Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA
Garfein RS, Liu L, Cuevas-Mota J, Collins K, Muñoz F, Catanzaro DG, Moser K, Higashi J, et al. (16 authors)
Emerging infectious diseases · 2018-10
Abstract
We assessed video directly observed therapy (VDOT) for monitoring tuberculosis treatment in 5 health districts in California, USA, to compare adherence between 174 patients using VDOT and 159 patients using in-person directly observed therapy (DOT). Multivariable linear regression analyses identified participant-reported sociodemographics, risk behaviors, and treatment experience associated with adherence. Median participant age was 44 (range 18-87) years; 61% of participants were male. Median fraction of expected doses observed (FEDO) among VDOT participants was higher (93.0% [interquartile range (IQR) 83.4%-97.1%]) than among patients receiving DOT (66.4% [IQR 55.1%-89.3%]). Most participants (96%) would recommend VDOT to others; 90% preferred VDOT over DOT. Lower FEDO was independently associated with US or Mexico birth, shorter VDOT duration, finding VDOT difficult, frequently taking medications while away from home, and having video-recording problems (p<0.05). VDOT cost 32% (range 6%-46%) less than DOT. VDOT was feasible, acceptable, and achieved high adherence at lower cost than DOT.
MeSH terms
- Humans
- Tuberculosis
- Antitubercular Agents
- Directly Observed Therapy
- Video Recording
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Middle Aged
- Costs and Cost Analysis
- California
- Female
- Male
- Medication Adherence
- Young Adult